Calliditas Therapeutics AB (publ) (CALT) News Today → **Breaking News** LIttle Known Biotech Company Does $41 Million In Q1! (From Huge Alerts) (Ad) Free CALT Stock Alerts $22.15 -0.04 (-0.18%) (As of 01:41 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 18 at 10:40 PM | finanznachrichten.deCalliditas Therapeutics: In-Person & Virtual R&D Day: The Anti-Fibrotic Effects of Setanaxib and TARPEYO's Mode of ActionMay 16, 2024 | prnewswire.comIn-Person & Virtual R&D Day: The Anti-Fibrotic Effects of Setanaxib and TARPEYO's Mode of ActionMay 16, 2024 | finance.yahoo.comInvitation to the presentation of Calliditas´s interim report January - March 2024May 15, 2024 | prnewswire.comCalliditas Therapeutics to Present Data at ERA 2024 May 23 - 26 in StockholmMay 15, 2024 | prnewswire.comNotice of annual general meeting of Calliditas Therapeutics AB (publ)May 14, 2024 | finance.yahoo.comExploring Three Swedish Growth Companies With High Insider Ownership On The Swedish ExchangeMay 14, 2024 | marketbeat.comCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Shares Gap Up to $21.02Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Shares Gap Up to $21.02May 14, 2024 | prnewswire.comCalliditas' Partner Everest Medicines Starts Commercial Launch of Nefecon in ChinaMay 6, 2024 | markets.businessinsider.comWhat Wall Street expects from Calliditas Therapeutics (spons ADRs)'s earningsMay 6, 2024 | msn.comCalliditas releases phase 2 results on head and neck cancer asset setanaxibMay 6, 2024 | prnewswire.comCalliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxibApril 30, 2024 | marketbeat.comCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Shares Gap Up to $18.65Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Shares Gap Up to $18.65April 29, 2024 | marketbeat.comCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Stock Price Down 9.3%Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Stock Price Down 9.3%April 26, 2024 | marketbeat.comCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Short Interest Up 121.9% in AprilCalliditas Therapeutics AB (publ) (NASDAQ:CALT - Get Free Report) saw a large increase in short interest during the month of April. As of April 15th, there was short interest totalling 7,100 shares, an increase of 121.9% from the March 31st total of 3,200 shares. Based on an average trading volume of 7,300 shares, the days-to-cover ratio is presently 1.0 days.April 24, 2024 | finance.yahoo.comCalliditas Therapeutics' 2023 Annual Report PublishedApril 24, 2024 | prnewswire.comCalliditas Announces Positive NefIgArd Open Label Extension ResultsApril 22, 2024 | marketbeat.comCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Trading Down 6.4%Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Trading Down 6.4%April 19, 2024 | marketbeat.comCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Trading 3.4% Higher Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Stock Price Up 3.4%April 19, 2024 | benzinga.comLatest News for Calliditas Therapeutics Stock (NASDAQ:CALT)April 18, 2024 | marketbeat.comCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Shares Gap Down to $18.74Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Shares Gap Down to $18.74April 18, 2024 | prnewswire.comCalliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024April 11, 2024 | markets.businessinsider.comBuy Rating Affirmed for Calliditas Therapeutics Amid Positive Market Trends and Upcoming CatalystsApril 11, 2024 | marketbeat.comCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Short Interest Down 56.2% in MarchCalliditas Therapeutics AB (publ) (NASDAQ:CALT - Get Free Report) saw a significant drop in short interest in March. As of March 31st, there was short interest totalling 3,200 shares, a drop of 56.2% from the March 15th total of 7,300 shares. Based on an average daily trading volume, of 7,900 shares, the days-to-cover ratio is presently 0.4 days.April 10, 2024 | marketbeat.comCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Stock Price Down 8.3%Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Trading Down 8.3%April 9, 2024 | finance.yahoo.comCalliditas Therapeutics to Attend Conferences in AprilApril 9, 2024 | prnewswire.comCalliditas Therapeutics to Attend Conferences in AprilApril 8, 2024 | markets.businessinsider.comCalliditas Gets Notice Of Allowance For U.S. Patent Application Covering Setanaxib To Treat CancerApril 8, 2024 | prnewswire.comCalliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos AiresApril 8, 2024 | prnewswire.comCalliditas receives notice of allowance for United States patent application covering setanaxib in cancer treatmentApril 7, 2024 | cnn.comCalliditas Therapeutics AB Sponsored ADRApril 4, 2024 | marketbeat.comCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Shares Gap Up to $21.25Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Shares Gap Up to $21.25April 1, 2024 | marketbeat.comCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Shares Up 4.5%Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Trading 4.5% HigherMarch 31, 2024 | marketbeat.comCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Sees Significant Growth in Short InterestCalliditas Therapeutics AB (publ) (NASDAQ:CALT - Get Free Report) was the recipient of a significant increase in short interest in March. As of March 15th, there was short interest totalling 7,300 shares, an increase of 15.9% from the February 29th total of 6,300 shares. Based on an average daily volume of 13,500 shares, the short-interest ratio is currently 0.5 days.March 28, 2024 | marketbeat.comCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Shares Gap Down to $21.49Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Shares Gap Down to $21.49March 26, 2024 | marketbeat.comCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Stock Price Down 3.8%Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Trading Down 3.8%March 19, 2024 | marketbeat.comCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Shares Down 7.2% Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Trading Down 7.2%March 18, 2024 | marketbeat.comCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Shares Gap Down to $22.30Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Shares Gap Down to $22.30March 14, 2024 | marketbeat.comCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Sees Large Increase in Short InterestCalliditas Therapeutics AB (publ) (NASDAQ:CALT - Get Free Report) was the target of a significant growth in short interest in February. As of February 29th, there was short interest totalling 6,300 shares, a growth of 37.0% from the February 14th total of 4,600 shares. Based on an average daily trading volume, of 16,000 shares, the days-to-cover ratio is presently 0.4 days.March 11, 2024 | prnewswire.comEverest Medicines' Partner Calliditas Therapeutics Announces U.S. FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for Nefecon®March 6, 2024 | finanznachrichten.deCalliditas Therapeutics: Calliditas announces an additional seven year orphan drug exclusivity period for TARPEYOMarch 6, 2024 | finanznachrichten.deCalliditas Therapeutics: Calliditas announces an additional seven year orphan drug exclusivity period for TARPEYO®March 6, 2024 | prnewswire.comCalliditas announces an additional seven year orphan drug exclusivity period for TARPEYO®March 1, 2024 | prnewswire.comCalliditas Therapeutics to Attend Investor Conferences in MarchFebruary 26, 2024 | msn.comFulcrum Therapeutics Q4 2023 Earnings PreviewFebruary 25, 2024 | msn.comCalliditas Therapeutics AB (CALT) Price Target Increased by 5.27% to 42.86February 22, 2024 | finance.yahoo.comCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Q4 2023 Earnings Call TranscriptFebruary 22, 2024 | markets.businessinsider.comCalliditas Therapeutics: Strong Sales and FDA Approval Propel Buy RatingFebruary 21, 2024 | marketbeat.comCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Sees Strong Trading VolumeCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Sees Unusually-High Trading VolumeFebruary 21, 2024 | prnewswire.comCalliditas Year-end report, January - December 2023February 14, 2024 | finance.yahoo.comInvitation to the presentation of Calliditas´ Year-end report January - December 2023 Get Calliditas Therapeutics AB (publ) News Delivered to You Automatically Sign up to receive the latest news and ratings for CALT and its competitors with MarketBeat's FREE daily newsletter. Email Address **Breaking News** LIttle Known Biotech Company Does $41 Million In Q1! (Ad)Learn more about why Zack’s has increased its price target on this company to a whopping $23.25! Click for Zack's full report CALT Media Mentions By Week CALT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CALT News Sentiment▼0.370.42▲Average Medical News Sentiment CALT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CALT Articles This Week▼82▲CALT Articles Average Week Get Calliditas Therapeutics AB (publ) News Delivered to You Automatically Sign up to receive the latest news and ratings for CALT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: GH Research News AnaptysBio News CureVac News Pharming Group News Mineralys Therapeutics News Lyell Immunopharma News Cogent Biosciences News Zymeworks News Savara News Silence Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CALT) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressDoes this make you sick?Allegiance GoldThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldUrgent Nvidia WarningAltimetryThis Apple-like Innovator is Revolutionizing HealthcareWall Street Star**Breaking News** LIttle Known Biotech Company Does $41 Million In Q1! Huge Alerts Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Calliditas Therapeutics AB (publ) Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
